7 results
The objective of the BRAVO 2/3 study is to assess the safety and efficacy of using bivalirudin instead of unfractionated heparin (UFH) in transcatheter aortic valve replacements (TAVR).
Primary objective: - to evaluate the effects of fampridine on eye movements in MS patients with a unilateral or bilateral INO. Secondary objectives:- to determine whether there is an association between MRI signal of the medial longitudinal…
The study hypothesis is that anticoagulation with bivalirudin for primary PCI in STEMI subjects with a 4 h infusion post-PCI will reduce infarct size compared with anticoagulation with UFH as assessed by CMR 5 days after the index event.The primary…
1) To demonstrate that trans-radial intervention as compared to femoral access site is associated to lower rate of the composite endpoint of death, MI or stroke within the first 30 days after randomization in acute coronary syndrome patients…
The purpose of the trial is to show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in patients with STE-ACS, with an onset of symptoms of >20 minutes and <12 hours,…
Primary: The primary objective of the study is to assess the effect of long term treatment with prolonged release fampridine 10 mg twice daily on the physical component scale (PCS) of the Short Form (36) Health Status Questionnaire (SF 36) as…
The objectives of this study in MS subjects treated with prolonged-release fampridine 10 mg twice daily compared with subjects treated with placebo are: - To assess the effect of prolonged-release fampridine over 24 weeks on the following parameters…